express scripts

Bank of America reiterated its Buy rating on Express Scripts (NASDAQ: ESRX). At the same time, Bank of America decided to leave its price target on the company's stock unchanged at $67. On Thursday, Express Scripts closed the day at $54.06.

“This past Tuesday, Walgreen Co. (NYSE: WAG) announced it will not participate in the Express Scripts Inc. (NASDAQ: ESRX) pharmacy network beginning on 1/1/2012,” JP Morgan wrote in a report this morning. “We remain hopeful the two companies can come to a mutually agreeable contract. However,...

Jefferies is out with its report today on Express Scripts (NASDAQ: ESRX), reiterating Buy. In a note to clients, Jefferies writes, "WAG (NYSE: WAG)/ESRX contract negotiations may be stalled for the moment but are far from dead. Potential earnings loss at WAG from a terminated ESRX relationship...

J.P. Morgan is out with its report on Express Scripts (NASDAQ: ESRX), maintaining Overweight. In a note to clients, J.P. Morgan writes, "Our rating on Express Scripts is Overweight. We continue to point to the positive fundamental outlook for the PBM industry, based on the opportunity around...

J.P. Morgan is out with its report today on Express Scripts (NASDAQ: ESRX), maintaining Overweight. In a note to clients, J.P. Morgan writes, "Our rating on Express Scripts shares is Overweight. We continue to point to the positive fundamental outlook for the PBM industry, based on the opportunity...

Express Scripts Inc. (NASDAQ: ESRX) reported 1Q11 non-GAAP EPS of $0.66 below MS' $0.70 and consensus' $0.69, Morgan Stanley reports. “Results were driven be a decline in script count, down 5.2 million or 2.7% sequentially and down 0.3% y/y,” Morgan Stanley writes. “Previously announced contract...

Goldman Sachs is out with its report today on Express Scripts (NASDAQ: ESRX), maintaining Neutral. In a note to clients, Goldman Sachs writes, "ESRX reported 1Q adjusted EPS of $0.66 and a rare miss versus us and the Street at $0.70 and $0.69. The shortfall relative to our model was driven by a...

Momentum in equities should parlay into solid performance for larger cap healthcare names such as pharmacy benefit managers, labs and hospitals. In the report, Jefferies writes, “We continue to believe that [Quest Diagnostics] DGX, [Express Scripts, Inc.] ESRX, [Medco Health Solutions, Inc.] MHS (...

J.P. Morgan has reiterated Express Scripts' (NASDAQ: ESRX) Overweight Rating. According to J.P. Morgan, “We reiterate our OW rating on ESRX. Shares trade at 17.0x our FY11 adjusted EPS estimate of $3.20, representing a discount to the company's historical valuation and our projected EPS growth...

Jefferies is out with its report today on Express Scripts (NASDAQ: ESRX), raising its price target from $57.50 to $69. In a note to clients, Jefferies writes, "ESRX is strong near-term 'beta' play buoyed by its consistent operational and financial performance. Bigger earnings opportunities remain...

Jefferies & Company has raised the price target on Express Scripts (NASDAQ: ESRX) from $57.50 to $69 and maintains its Buy rating.

Goldman Sachs is out with its report today on Express Scripts (NASDAQ: ESRX), raising its price target from $58 to $61. In a note to clients, Goldman Sachs writes, "ESRX reported 4Q EPS of $0.71, versus our $0.69 and the Street at $0.70. While we anticipate some initial investor focus on pricing (...

UBS has changed its price target on the following companies: Willbros Group (NYSE: WG) from $9.10 to $7.75. Medco Health Solutions (NYSE: MHS) from $70 to $76. Express Scripts (NASDAQ: ESRX) from $63 to $66. Energy XXI (NASDAQ: EXXI) from $26 to $34. Ann Taylor (NYSE: ANN) from $30 to $32.

Goldman Sachs is adjusting its cash EPS reporting for Medco Health Solutions (NYSE: MHS) and Express Scripts Inc. (NASDAQ: ESRX) to exclude all amortization expenses (also legacy amortization) from its previous reporting methodology of only excluding Merck & Co. Inc. (NYSE: MRK)-related...

After the close, Express Scripts, Inc. (NASDAQ: ESRX) reported 3Q10 results and provided initial 2011 guidance. “In our view, the key focus is on the 2011 guidance, which we view positively, as the lower end of the range exceeded the current Street consensus,” J.P. Morgan writes. “Importantly, we...